Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 354-361

  Massuti, Bartomeu ^a   Cobo, Manuel ^b   Camps, Carlos ^c   Dómine, Manuel ^d   Provencio, Mariano ^e   Alberola, Vicente ^f   Viñolas, Nuria ^g   Rosell, Rafael ^h   Tarón, Miguel ⁱ   Gutiérrez Calderón, Vanesa ^b   Lardelli, Pilar ^j   Alfaro, Vicente ^j   Nieto, Antonio ^j   Isla, Dolores ^k  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ INSTITUT UNIVERSITARI DEXEUS   (Spain)

^j PHARMAMAR S A   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

more..

Author keywords

Chemotherapy; Gene signature; Lung; NSCLC; Response; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; ONCOPROTEIN; PLATINUM; PROTEIN XPG; TRABECTEDIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER PATIENT; CELLULITIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MOTION SICKNESS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESPIRATORY FAILURE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DIOXOLES; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PLATINUM; TETRAHYDROISOQUINOLINES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84860516956     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.002     Document Type: Article

References (42)

1. Garcia-Carbonero R., Supko J.G., Manola J., Seiden M.V., Harmon D., Ryan D.P., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004, 22:1480-1490.
2. Yovine A., Riofrio M., Blay J.Y., Brain E., Alexandre J., Kahatt C., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004, 22:890-899.
3. Le Cesne A., Blay J.Y., Judson I., Van Oosterom A., Verweij J., Radford J., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005, 23:576-584.
4. Sessa C., De Braud F., Perotti A., Bauer J., Curigliano G., Noberasco C., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005, 23:1867-1874.
5. Del Campo J.M., Roszak A., Bidzinski M., Ciuleanu T.E., Hogberg T., Wojtukiewicz M.Z., et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5mg/m2 24h or 1.3mg/m2 3h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009, 20:1794-1802.
6. Krasner C.N., McMeekin D.S., Chan S., Braly P.S., Renshaw F.G., Kaye S., et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007, 97:1618-1624.
7. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F.M., et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107-3114.
8. Monk B.J., Herzog T.J., Kaye S.B., Krasner C.N., Vermorken J.B., Muggia F., et al. Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. J Clin Oncol 2011, 29(Suppl.). abstr 5046.
9. Michaelson M.D., Gilligan T., Oh W., Kantoff P., Taplin M., Izquierdo M.A., et al. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 2005, 23:4517.
10. Gurtler J.S., Goldstein L., Delprete S., Tjulandin S., Semiglazov V., Sternas L., et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 2005, 23:625.
11. Zelek L., Yovine A., Brain E., Turpin F., Taamma A., Riofrio M., et al. A phase II study of Yondelis((R)) (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006, 94:1610-1614.
12. Demetri G.D., Chawla S.P., von Mehren M., Ritch P., Baker L.H., Blay J.Y., et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196.
13. Faircloth G.T., Avila F., Fernandez Puentes F., Rinehart K., Garcia-Rocha M., Garcia Gravalos D., et al. ET000632 Ecteinascidin (ET) 743: developmental status of a marine (M) derived anticancer compound (AC). ECCO 8 The European Cancer Conference. Eur J Cancer 1995, 31A(S5):S26-S27.
14. Rinehart K.L., Gravalos L.G., Faircloth G., Jimeno J. ET000256 ET743: preclinical antitumor development of a marine derived natural product. Annual Meeting AACR American Association for Cancer Research 1995, p. 390. Abs 2322.
15. Izbicka E., Lawrence R., Raymond E., Eckhardt G., Faircloth G., Jimeno J., et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998, 9:981-987.
16. Hendriks H.R., Fiebig H.H., Giavazzi R., Langdon S.P., Jimeno J.M., Faircloth G.T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999, 10:1233-1240.
17. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9:2157-2163.
18. Zewail-Foote M. Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999, 42:2493-2497.
19. Herrero A.B., Martin-Castellanos C., Marco E., Gago F., Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006, 66:8155-8162.
20. Soares D.G., Escargueil A.E., Poindessous V., Sarasin A., de Gramont A., Bonatto D., et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007, 104:13062-13067.
21. Martinez N., Sanchez-Beato M., Carnero A., Moneo V., Tercero J.C., Fernandez I., et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005, 4:814-823.
22. Italiano A., Laurand A., Laroche A., Casali P., Sanfilippo R., Le Cesne A., et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011, 117:3445-3456.
23. Maier A., Korrat A., Metz T., Galmarini C., Aviles P., Tercero J.C., et al. Evaluation of antitumor efficacy of trabectedin in patient derived tumor xenografts in vitro and in vivo, and determination of a predictive gene signature. AACR American Association for Cancer Research; 101th Annual Meeting 2010, Abstract 2598.
24. Rosell R, Martinez N, Rodriguez S, Chaib I, Grosso F, Taron M, et al. Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients. AACR Meeting Abstracts 2007, 297. (Abstract C127).
25. ®) in advanced pre-treated sarcomas. ECCO 14. The European Cancer Conference, Barcelona, Abstract Book 2007, 403. (abstract 7505).
26. Schoffski P., Taron M., Jimeno J., Grosso F., Sanfilipo R., Casali P.G., et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin. Eur J Cancer 2011, 47:1006-1012.
27. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
28. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
29. Quinn J.E., Kennedy R.D., Mullan P.B., Gilmore P.M., Carty M., Johnston P.G., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-6228.
30. Olaussen K.A., Mountzios G., Soria J.C. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007, 13:284-289.
31. Li Q., Gardner K., Zhang L., Tsang B., Bostick-Bruton F., Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998, 273:23419-23425.
32. Li Q., Yu J.J., Mu C., Yunmbam M.K., Slavsky D., Cross C.L., et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000, 20:645-652.
33. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
34. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
35. Casali P.G., Sanfilippo R., D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol 2010, 22:342-346.
36. Ganjoo K.N., Patel S.R. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother 2009, 10:2735-2743.
37. Schoffski P., Flores G., Wildiera H., Stefan C., Rogiers A., Dumez H. Trabectedin (YondelisR; ET-743): a drug of marine origin for soft-tissue sarcoma. Hosp Pharm Eur 2008, 37(March/April):19-23.
38. Schoffski P., Dumez H., Wolter P., Stefan C., Wozniak A., Jimeno J., et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008, 9:1609-1618.
39. Zelek L., Yovine A., Brain E., Turpin F., Taamma A., Riofrio M., et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006, 94:1610-1614.
40. Carter N.J., Keam S.J. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007, 67:2257-2276.
41. Cioffi A., LeCesne A., Blay J.-Y., Delaloge S., Yovine A., Maki R., et al. Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol 2009, 27:e13510. abstr.
42. Garcia-Carbonero R., Supko J.G., Maki R.G., Manola J., Ryan D.P., Harmon D., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005, 23:5484-5492.